Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PGNY 
Progyny Inc (PGNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: PGNY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $28.25
1 Year Target Price $28.25
| 4 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 11.25% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.67B USD | Price to earnings Ratio 32.9 | 1Y Target Price 28.25 |
Price to earnings Ratio 32.9 | 1Y Target Price 28.25 | ||
Volume (30-day avg) 10 | Beta 1.34 | 52 Weeks Range 13.39 - 26.76 | Updated Date 10/21/2025 |
52 Weeks Range 13.39 - 26.76 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When - | Estimate 0.1251 | Actual - |
Profitability
Profit Margin 4.28% | Operating Margin (TTM) 7.32% |
Management Effectiveness
Return on Assets (TTM) 6.57% | Return on Equity (TTM) 10.94% |
Valuation
Trailing PE 32.9 | Forward PE 10.43 | Enterprise Value 1487351504 | Price to Sales(TTM) 1.34 |
Enterprise Value 1487351504 | Price to Sales(TTM) 1.34 | ||
Enterprise Value to Revenue 1.2 | Enterprise Value to EBITDA 18.41 | Shares Outstanding 85982409 | Shares Floating 79582738 |
Shares Outstanding 85982409 | Shares Floating 79582738 | ||
Percent Insiders 7.57 | Percent Institutions 104.5 |
Upturn AI SWOT
Progyny Inc
Company Overview
History and Background
Progyny Inc. was founded in 2008. Initially a digital health company, it transitioned to a fertility benefits management company. It went public in 2019. Progyny has expanded its services through technology and strategic partnerships.
Core Business Areas
- Fertility Benefits Management: Progyny provides comprehensive fertility benefits solutions, covering fertility treatments (IVF, IUI, egg freezing, etc.), genetic testing, and related services. This includes access to a network of fertility specialists.
- Pharmacy Benefits: Progyny Rx manages fertility medications, providing cost-effective and convenient access to necessary drugs. This is usually integrated with the fertility benefit program to facilitate seamless services.
Leadership and Structure
Peter V. Niekerk serves as the CEO. The company has a board of directors overseeing strategic direction. Organizational structure is designed to support both benefits management and pharmacy operations.
Top Products and Market Share
Key Offerings
- Progyny Fertility Benefit: Comprehensive fertility benefits solution for employers. Market share estimated to be 25% in the fertility benefits management market. Competitors include WINFertility, Carrot Fertility, and Mercer.
- Progyny Rx: Pharmacy benefits management service specializing in fertility medications. Revenue data not publicly disclosed as a standalone product. Competitors include specialized pharmacies and PBMs offering fertility medication solutions.
Market Dynamics
Industry Overview
The fertility benefits market is growing, driven by increasing awareness of infertility, rising demand for fertility treatments, and employer adoption of fertility benefits to attract and retain talent. The industry is characterized by technological advancements and increasing emphasis on personalized care.
Positioning
Progyny is positioned as a premium, comprehensive fertility benefits provider, emphasizing high-quality care and superior outcomes. Competitive advantages include its network of fertility specialists, technology platform, and integrated pharmacy benefits.
Total Addressable Market (TAM)
Estimated TAM for fertility benefits market is approximately $30 Billion. Progyny is positioned to capture a significant portion of the TAM due to its large presence with Fortune 500 companies and end-to-end suite of offerings.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Comprehensive fertility benefits platform
- Network of high-quality fertility specialists
- Integrated pharmacy benefits (Progyny Rx)
- Scalable technology platform
- Strong growth in membership
Weaknesses
- High cost compared to some competitors
- Reliance on large employer clients
- Limited geographic coverage outside the US
- Potential for adverse selection in benefits utilization
Opportunities
- Expand into new markets and geographies
- Increase penetration within existing employer clients
- Develop new fertility-related services and products
- Acquire smaller competitors to expand market share
- Further integration with healthcare providers
Threats
- Increased competition from other fertility benefits providers
- Changes in healthcare regulations
- Economic downturn impacting employer spending on benefits
- Adverse selection impacting the profitability of benefits plans
- Decline in birth rates.
Competitors and Market Share
Key Competitors
- WINFertility
- Carrot Fertility
- Kindbody
Competitive Landscape
Progyny's advantages include its comprehensive platform, network of specialists, and integrated pharmacy benefits. Disadvantages may include higher cost compared to some competitors and reliance on large employer clients.
Growth Trajectory and Initiatives
Historical Growth: Progyny has experienced rapid revenue growth in recent years, driven by increasing adoption of fertility benefits and expansion of its membership base.
Future Projections: Analysts project continued revenue growth in the coming years, driven by the factors mentioned above.
Recent Initiatives: Recent initiatives include expanding its Progyny Rx pharmacy benefits program, and partnerships with fertility clinics and healthcare providers.
Summary
Progyny is a strong player in the fertility benefits management market with growing revenue and a healthy balance sheet. Its comprehensive platform and quality network are key strengths. However, it needs to address competition and the potential impact of economic downturns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Progyny Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-10-25 | CEO & Director Mr. Peter Anevski CPA | ||
Sector Healthcare | Industry Healthcare Plans | Full time employees 675 | Website https://www.progyny.com |
Full time employees 675 | Website https://www.progyny.com | ||
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.